Secukinumab MOA Animation

Created for Novartis; BioScience Communications
The project

In this 3D mechanism-of-action animation we introduced the role of IL-17 anatogonist sekukinumab in treating psoriasis. The audience was healthcare professionals becoming exposed to the idea treating inflammatory diseases with biologics. Because scientific accuacy was important in this story, we constructed the molecular players from peer-reviewed structural data. Evidence-based visualization is something at which AXS Studio excels.

Created for
Novartis
BioScience Communications

COVID-19 Update:
In alignment with public health directives, we continue to prioritize the safety of our staff and uninterrupted service to our clients.
We are open for business. Wishing you good health and resilience. We’re all in this together.